{
 "companyname": "SYNTA PHARMACEUTICALS CORP",
 "symbol": "SNTA",
 "description": "Pharmaceutical Preparations",
 "quarters": [
  {
   "cik": "0001157601",
   "companyname": "SYNTA PHARMACEUTICALS CORP",
   "entityid": 112818,
   "primaryexchange": "Nasdaq Global Market",
   "primarysymbol": "SNTA",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "11/5/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "9/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 3,
   "dcn": "0001104659-15-076292",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": 238000,
   "changeincurrentliabilities": 402000,
   "changeininventories": null,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": -13000,
   "cashfromfinancingactivities": 5516000,
   "cashfrominvestingactivities": 23620000,
   "cashfromoperatingactivities": -15602000,
   "cfdepreciationamortization": 166000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": 23633000,
   "netchangeincash": 13534000,
   "totaladjustments": 2026000,
   "ebit": -17394000,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 0,
   "incomebeforetaxes": -17628000,
   "interestexpense": -234000,
   "netincome": -17628000,
   "netincomeapplicabletocommon": -17628000,
   "researchdevelopmentexpense": 14413000,
   "totalrevenue": 0,
   "sellinggeneraladministrativeexpenses": 2981000,
   "commonstock": 14000,
   "deferredcharges": null,
   "cashandcashequivalents": 45537000,
   "cashcashequivalentsandshortterminvestments": 88252000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": 226000,
   "othercurrentassets": null,
   "othercurrentliabilities": null,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": 0,
   "propertyplantequipmentnet": 561000,
   "retainedearnings": -695708000,
   "totalassets": 91014000,
   "totalcurrentassets": 90227000,
   "totalcurrentliabilities": 30633000,
   "totalliabilities": 30644000,
   "totallongtermdebt": 11000,
   "totalreceivablesnet": null,
   "totalshorttermdebt": 6956000,
   "totalstockholdersequity": 60370000,
   "treasurystock": null
  },
  {
   "cik": "0001157601",
   "companyname": "SYNTA PHARMACEUTICALS CORP",
   "entityid": 112818,
   "primaryexchange": "Nasdaq Global Market",
   "primarysymbol": "SNTA",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "8/6/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "6/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 2,
   "dcn": "0001104659-15-056697",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": -846000,
   "changeincurrentliabilities": 1619000,
   "changeininventories": null,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": -27000,
   "cashfromfinancingactivities": 39497000,
   "cashfrominvestingactivities": -23019000,
   "cashfromoperatingactivities": -17730000,
   "cfdepreciationamortization": 168000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": -22992000,
   "netchangeincash": -1252000,
   "totaladjustments": 2070000,
   "ebit": -19504000,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 0,
   "incomebeforetaxes": -19800000,
   "interestexpense": -296000,
   "netincome": -19800000,
   "netincomeapplicabletocommon": -19800000,
   "researchdevelopmentexpense": 16377000,
   "totalrevenue": 0,
   "sellinggeneraladministrativeexpenses": 3127000,
   "commonstock": 13000,
   "deferredcharges": null,
   "cashandcashequivalents": 32003000,
   "cashcashequivalentsandshortterminvestments": 98334000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": 278000,
   "othercurrentassets": null,
   "othercurrentliabilities": null,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": 0,
   "propertyplantequipmentnet": 714000,
   "retainedearnings": -678080000,
   "totalassets": 101539000,
   "totalcurrentassets": 100547000,
   "totalcurrentliabilities": 32525000,
   "totalliabilities": 32557000,
   "totallongtermdebt": 32000,
   "totalreceivablesnet": null,
   "totalshorttermdebt": 9250000,
   "totalstockholdersequity": 68982000,
   "treasurystock": null
  },
  {
   "cik": "0001157601",
   "companyname": "SYNTA PHARMACEUTICALS CORP",
   "entityid": 112818,
   "primaryexchange": "Nasdaq Global Market",
   "primarysymbol": "SNTA",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "5/7/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "3/31/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 1,
   "dcn": "0001104659-15-035100",
   "currencycode": "USD",
   "crosscalculated": false,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": 289000,
   "changeincurrentliabilities": 23000,
   "changeininventories": null,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": 0,
   "cashfromfinancingactivities": -2311000,
   "cashfrominvestingactivities": 8317000,
   "cashfromoperatingactivities": -18775000,
   "cfdepreciationamortization": 169000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": 8317000,
   "netchangeincash": -12769000,
   "totaladjustments": 1932000,
   "ebit": -20332000,
   "costofrevenue": null,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 0,
   "incomebeforetaxes": -20707000,
   "interestexpense": -375000,
   "netincome": -20707000,
   "netincomeapplicabletocommon": -20707000,
   "researchdevelopmentexpense": 16182000,
   "totalrevenue": 0,
   "sellinggeneraladministrativeexpenses": 4150000,
   "commonstock": 11000,
   "deferredcharges": null,
   "cashandcashequivalents": 33255000,
   "cashcashequivalentsandshortterminvestments": 76606000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": 564000,
   "othercurrentassets": null,
   "othercurrentliabilities": null,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": 0,
   "propertyplantequipmentnet": 855000,
   "retainedearnings": -658280000,
   "totalassets": 79392000,
   "totalcurrentassets": 77973000,
   "totalcurrentliabilities": 30920000,
   "totalliabilities": 33252000,
   "totallongtermdebt": 2332000,
   "totalreceivablesnet": null,
   "totalshorttermdebt": 9263000,
   "totalstockholdersequity": 46140000,
   "treasurystock": null
  }
 ]
}